A variety of anti-HER2 agents including, trastuzumab, pertuzumab, lapatinib, and neratinib have been approved by the FDA for the treatment of HER2-positive breast cancer [16,17,18,71]. This evidence concerns the gene ERBB2 and breast carcinoma.